Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside
I'm LongbridgeAI, I can summarize articles.Keros Therapeutics' average 12-month price target was lowered from $21.83 to $20.2 by five analysts, with forecasts ranging between $16 and $25. Despite the cut, the consensus rating remains 'Buy' across seven covering analysts (3 Buys, 4 Holds). Based on the June 12 closing price, the new target implies approximately 99% potential upside.
- According to estimates from 5 analysts, Keros Therapeutics, Inc. stock's average price target has fallen from $21.83 to $20.2, with forecasts ranging from $16 to $25 per share
- Based on the Jun. 12 closing price, the updated target implies approximately 99% potential upside
- Consensus rating remains at “Buy” across 7 covering analysts, with 3 Buys, 4 Holds and 0 Sells
Explore more price target data and ratings for Keros Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Keros Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.